Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Sargramostim |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Sargramostim | Leukine | GM-CSF|Prokine |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06528496 | Phase II | Irinotecan Doxorubicin Ifosfamide Sargramostim Etoposide Temozolomide Carboplatin Naxitamab Vincristine Sulfate Topotecan Cyclophosphamide | N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma | Recruiting | USA | 0 |
NCT01827137 | Phase I | WT1 vaccine Lenalidomide Sargramostim | WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation | Completed | USA | 0 |
NCT02009397 | Phase Ib/II | Sargramostim Ipilimumab | A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients | Completed | USA | 0 |
NCT02636582 | Phase II | Sargramostim Nelipepimut-S Plus GM-CSF | Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer | Completed | USA | 0 |
NCT01570036 | Phase II | E75 Sargramostim Trastuzumab | Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax | Completed | USA | 0 |
NCT01903330 | Phase II | Bevacizumab Cyclophosphamide Sargramostim | ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme | Unknown status | USA | 0 |
NCT01857934 | Phase II | Doxorubicin Sargramostim Aldesleukin Vincristine Sulfate Filgrastim Tretinoin Levetiracetam Cisplatin + Etoposide Hu14.18K322A Busulfan + Melphalan Cyclophosphamide + Topotecan | Therapy for Children With Advanced Stage Neuroblastoma | Active, not recruiting | USA | 0 |
NCT02339571 | Phase II | Sargramostim Nivolumab Ipilimumab | Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | Recruiting | USA | 0 |
NCT03126916 | Phase III | Doxorubicin 131I-MIBG Sargramostim Etoposide Melphalan Busulfan Isotretinoin Vincristine Sulfate Cisplatin Cyclophosphamide Thiotepa Dexrazoxane Lorlatinib Carboplatin Aldesleukin Topotecan Dinutuximab | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Active, not recruiting | USA | CAN | 1 |
NCT03761914 | Phase Ib/II | Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Active, not recruiting | USA | 0 |
NCT01479244 | Phase III | E75 Sargramostim | Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence | Completed | USA | ROU | POL | ISR | HUN | GBR | FRA | DEU | CAN | BGR | 3 |
NCT05242965 | Phase II | Sargramostim Sargramostim + STEMVAC | A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT00621036 | Phase II | Methotrexate Thiotepa Sargramostim | Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma | Withdrawn | USA | 0 |
NCT02411786 | Phase I | pTVG-AR Sargramostim | A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF | Completed | USA | 0 |
NCT02620865 | Phase Ib/II | Paclitaxel Aldesleukin Oxaliplatin Sargramostim Gemcitabine Fluorouracil + Leucovorin | Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02297698 | Phase II | Sargramostim Trastuzumab E75 | Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients | Completed | USA | 0 |
NCT01530984 | Phase II | Sargramostim Ipilimumab | Ipilimumab and GMCSF Immunotherapy for Prostate Cancer | Withdrawn | USA | 0 |
NCT02510950 | Phase I | Sargramostim Poly ICLC Temozolomide | Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma | Terminated | USA | 0 |